Urology Times staff

“We need to treat our patients with stones, both medically and surgically,” says Glenn M. Preminger, MD.

“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.

Interim results from the ROBUST III trial were presented at the 2021 AUA Annual Meeting.

“We are truly embarking at this moment on the next frontier in urology with these types of cellular therapies,” says Melissa R. Kaufman, MD, PhD.

“We recommend doing the spot cautery,” says Andrew Higgins, MD.

“Even in patients that have only been single-stone formers, especially those that have required surgical stone removal, we believe that medical prevention is warranted to prevent recurrent stones,” says Glenn M. Preminger, MD.

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

“Tramadol is a mixed-class medication and it has weak opioid agonist activity. Normally, we consider that a safer option compared to other opioids, but it's actually a pro drug, so it has to be metabolized to have an effect,” says Sarah F. Faris, MD.

Michael S. Cookson, MD, previews the 2021 AUA Annual Meeting, with a focus on prostate, bladder, and kidney cancer. His in-depth analysis covers the plenary sessions, late-breaking abstracts, and other abstracts of interest.

“It was nice to use the military health system to look at the population, which tends to be very diverse…[It allowed] us to get pretty large numbers to make some better conclusions about what’s already been established in this population,” says David A. Klein, MD, MPH.

Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.

“We have to be really careful prescribing tramadol and be aware that [it] can have really variable effects for patients,” says Sarah F. Faris, MD.

“When a man initially presents with metastatic disease, or fails initial systemic therapy, our approach has to be different. We are more concerned that their disease is more aggressive,” says Leonard Gomella, MD.

“Through these 2 small punctures, we can manipulate the device with the methodology to sample the entire prostate, both anterior apical and the posterior regions, where we find the vast majority of our cancers,” says Matthew A. Allaway, MD.

“Appropriately selecting your patient will result in a successful telehealth visit,” says Nitya E. Abraham, MD.

“A lot of clinicians are seeing transgender and gender-diverse people in their practice, whether it’s urology, whether it’s primary care, whether it’s other subspecialties…[They should have an understanding] that transgender and gender-diverse people are at a higher risk of a multitude of mental health diagnoses,” says David A. Klein, MD, MPH.

“The transperineal [prostate biopsy] approach is safer because the needles are passed through the perineal skin…so, we can sterilize that skin and if we enter through that passageway, we mitigate, if not eliminate, the risk of infection and sepsis,” says Matthew J. Allaway, MD.

“Transgender and gender-diverse people are at a higher risk of a multitude of mental health diagnoses, [which] really lends itself to a sensitive psycho-social history regardless of the specialty,” says David A. Klein, MD, MPH.

“The 3 major barriers we face [are] training, equipment, and reimbursement,” says Matthew A. Allaway, MD.

“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.

In this interview, Nicole L. Miller, MD, discusses her institution’s enhanced recovery after surgery protocol for ureteroscopy, which eliminates the use of opioids in patients undergoing this common procedure.

“This is an important form of providing health care, especially for people who have a lot of limitations in coming for in-person visits,” says Nitya E. Abraham, MD.

“From a clinician’s perspective…these medications and these diagnoses happen when there’s not enough care from the start,” says David A. Klein, MD, MPH.

“We found a majority of patients with televisits were satisfied, with many saying it was easy to schedule, easy to comfortably share sensitive information with their doctor, and with the most surprising [finding] being 80% saying they would choose it again over an in-person visit,” says Christina Shin, BA.

“In terms of patients having Botox, we have to be individualized to some extent where if you feel someone's at very high risk of bleeding…then maybe you will stop the blood thinners,” says Jai Seth, MD.

Risk factors Dr.Zhang highlights include site of metastases, PSA response, and metastases burden.

“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.

“The MRI/ultrasound-guided transperineal approach allows easy access to anterior prostate tumors,” says Marc A. Bjurlin, DO, MSc, FACOS, in this video.

Amy E. Krambeck, MD, discusses her recent trial comparing the efficacy of Trilogy and ShockPulse-SE lithotripters used in percutaneous nephrolithotomy.

Urology areas covered for this FDA clearance include conditions of the prostate, bladder, kidneys, and genitalia.